Topical Tranexamic Acid (TXA) in Joint Arthroplasty
| Status: | Completed |
|---|---|
| Conditions: | Arthritis, Osteoarthritis (OA), Orthopedic |
| Therapuetic Areas: | Rheumatology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/26/2019 |
| Start Date: | April 2013 |
| End Date: | January 2019 |
Topical Application of Tranexamic Acid in Joint Arthroplasty
The objective of this study is to evaluate the efficacy of topical tranexamic acid (TXA) in
decreasing blood loss following both shoulder arthroplasty and primary total hip
arthroplasty. TXA functions to decrease blood loss by affecting the blood clotting system
within the body. The investigators hypothesize that topical application of TXA prior to
closure reduces postoperative bleeding as measured by absolute changes in postoperative
hemoglobin levels and surgical drain output. In addition, use of topically applied
tranexaminic acid may reduce the need for transfusions, the rates of hematomas, infections,
and length of hospital stay.
decreasing blood loss following both shoulder arthroplasty and primary total hip
arthroplasty. TXA functions to decrease blood loss by affecting the blood clotting system
within the body. The investigators hypothesize that topical application of TXA prior to
closure reduces postoperative bleeding as measured by absolute changes in postoperative
hemoglobin levels and surgical drain output. In addition, use of topically applied
tranexaminic acid may reduce the need for transfusions, the rates of hematomas, infections,
and length of hospital stay.
Inclusion Criteria:
- Shoulders: All adult patients over the age of 18 scheduled for a primary total
arthroplasty or a primary reverse shoulder arthroplasty will be eligible for inclusion
in the study.
Hips: All adult patients over the age of 18 scheduled for a primary total hip arthroplasty
will be eligible for inclusion in the study.
Exclusion Criteria:
- allergy to TXA, refusal of blood products, preoperative use of anticoagulant therapy
within 5 days of surgery, history of seizures, renal failure (creatine clearance
<30ml/min), bleeding disorders, venous thromboembolism (deep vein thrombosis and/or
pulmonary embolism), significant cardiac history (myocardial infarction, angina,
stroke, lower limb ischemia), or perioperative anemia (hemoglobin <11g/dl in females
and < 12g/dl in males).
We found this trial at
1
site
Greenville, South Carolina 29615
Principal Investigator: Brian Burnikel, MD
Phone: 864-454-7458
Click here to add this to my saved trials
